These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38833153)

  • 1. Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.
    Liu A; Zhang G; Yang Y; Xia Y; Li W; Liu Y; Cui Q; Wang D; Yu J
    Cancer Immunol Immunother; 2024 Jun; 73(8):152. PubMed ID: 38833153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.
    Liu A; Zhang G; Yang Y; Xia Y; Li W; Liu Y; Cui Q; Wang D; Zhao J; Yu J
    Int Immunopharmacol; 2023 Jan; 114():109391. PubMed ID: 36508919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
    Yuan S; Xia Y; Shen L; Ye L; Li L; Chen L; Xie X; Lou H; Zhang J
    Cancer Immunol Immunother; 2021 Feb; 70(2):533-546. PubMed ID: 32852602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
    Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
    Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.
    Gao S; Huang Q; Wei S; Lv Y; Xie Y; Hao Y
    Clinics (Sao Paulo); 2024; 79():100371. PubMed ID: 38735175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
    Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
    Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
    Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
    PeerJ; 2022; 10():e14566. PubMed ID: 36540802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction.
    Lei W; Wang W; Qin S; Yao W
    Sci Rep; 2024 Jul; 14(1):17511. PubMed ID: 39080372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram based on circulating lymphocyte subsets for predicting radiation pneumonia in esophageal squamous cell carcinoma.
    Zhang XZ; Tao SP; Liang SX; Chen SB; Liu FS; Jiang W; Chen MJ
    Front Immunol; 2022; 13():938795. PubMed ID: 36105795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The advanced lung cancer inflammation index (ALI) predicted the postoperative survival rate of patients with non-small cell lung cancer and the construction of a nomogram model.
    Ma S; Li Z; Wang L
    World J Surg Oncol; 2024 Jun; 22(1):158. PubMed ID: 38877553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China.
    Liang G; Hu Z; Xu Q; Wang G; Wang Y; Li X; Zhang W; Lei H
    Cancer Med; 2024 Aug; 13(16):e70115. PubMed ID: 39162396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction of A Nomogram Prediction Model for PD-L1 Expression 
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
    Hao L; Wang L; Zhang M; Yan J; Zhang F
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
    Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
    Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
    Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
    Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
    Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
    Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
    Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.